Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized natalizumab interval dosing in relapsing-remitting multiple sclerosis
NL-OMON43550Phase 4Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Vrije University Medical Center. Primary endpoint: Number of patients developing gadolinium-enhancing lesions on brain MRI. Started Nov 2016; status: active, not recruiting.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON43550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43550.